Gallium Citrate Ga 67

Drugspedia.net

|Gallium Citrate Ga 67

Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9

   


Gallium Citrate Ga 67

Dosage Form: Injection

FOR DIAGNOSTIC USE

DESCRIPTION: Gallium Citrate Ga 67 Injection is supplied in isotonic solution as a sterile, non-pyrogenic diagnostic radiopharmaceutical for intravenous administration. Each milliliter of the isotonic solution contains 74 MBq (2 mCi) of Gallium Ga 67 on the calibration date, as a complex formed from 9 ng Gallium Chloride Ga 67, 2 mg of sodium citrate, 6.8 mg sodium chloride, and 9 mg benzyl alcohol/mL added as preservative. The pH is adjusted to between 4.5-8 with hydrochloric acid and/or sodium hydroxide solution. Gallium Ga 67, with a half-life of 78.3 hours, is cyclotron produced by the proton irradiation of enriched zinc oxide, is essentially carrier-free and contains negligible concentrations of other radioactive isotopes.

The radionuclidic composition at calibration time is ≥99.89% Gallium Ga 67, ≤0.01% Gallium Ga 66 and ≤0.1% due to other radiocontaminants, each expressed as a percentage of total activity. The radionuclidic composition at expiration time is ≥99.89% Gallium Ga 67, essentially zero (0.0002%) Gallium Ga 66 and essentially zero of other radiocontaminants each expressed as a percentage of total activity.

The chemical structure for Gallium Citrate is shown below:

PHYSICAL CHARACTERISTICS

Gallium Ga 67 decays to stable Zinc Zn 67 by electron capture with a physical half-life of 78.3 hours.1

TABLE 1. Principal Radiation Emission Data
Radiation Mean %/Disintegration Mean Energy (keV)
1Kocher, David C., “Radioactive Decay Data Tables”, DOE/TIC-11026 (1981).
Gamma-3 35.7 93.3
Gamma-4 19.7 184.6
Gamma-6 16.0 300.2

EXTERNAL RADIATION

The specific gamma ray constant for Gallium Ga 67 is 5.58 microcoulombs/Kg-hr-MBq (0.80R/hr-mCi) at 1 cm. The first half value thickness of lead is 0.066 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.41 cm of Pb will decrease the external radiation exposure by a factor of 10.

TABLE 2. Radiation Attenuation By Lead Shielding

cm of Lead (Pb)
Radiation
Attenuation Factor

cm of Lead (Pb)
Radiation
Attenuation Factor
0.066 0.5 2.5 10-3
0.41 10-1 4.8 10-4
1.2 10-2

To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in Table 3.

TABLE 3. Gallium Ga 67 Decay Chart Half-Life 78.3 Hours

Hours
Fraction
Remaining

Hours
Fraction
Remaining

Hours
Fraction
Remaining
*Calibration Time
 0* 1.00 42 0.69 84 0.48
6 0.95 48 0.65 90 0.45
12 0.90 54 0.62 96 0.43
18 0.85 60 0.59 108 0.38
24 0.81 66 0.56 120 0.35
30 0.77 72 0.53 132 0.31
36 0.73 78 0.50 144 0.28
156 0.25
168 0.23

CLINICAL PHARMACOLOGY: Carrier-free Gallium Citrate Ga 67 Injection has been found to concentrate in certain viable primary and metastatic tumors, as well as focal site of infection. The mechanism of concentration is unknown, but investigational studies have shown that Gallium Ga 67 accumulates in lysosomes and is bound to a soluble intracellular protein.

It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of Gallium Ga 67 – other than tumors and sites of infection– is in the renal cortex. After the first day, the maximum concentration shifts to bone and lymph nodes, and after the first week, to liver and spleen. Gallium is excreted relatively slowly from the body. The average whole body retention is 65% after 7 days, with 26% having been excreted in the urine and 9% in the stools.

INDICATIONS AND USAGES: Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.

Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.

CONTRAINDICATIONS: None known.

WARNINGS: Because of the benzyl alcohol content, caution should be used in administration to newborns, particularly infants born prematurely, and individuals with impaired liver function.

Precautions

General

A thorough knowledge of the normal distribution of intravenously administered Gallium Citrate Ga 67 Injection is essential in order to accurately interpret pathologic studies.

The finding in an abnormal gallium concentration usually implies the existence of underlying pathology, but further diagnostic studies should be done to distinguish benign from malignant lesions. Gallium Citrate Ga 67 Injection is intended for use as an adjunct in the diagnosis of certain neoplasms. Certain pathologic conditions may yield up to 40% false negative gallium studies. Therefore, a negative study cannot be definitively interpreted as ruling out the presence of disease.

Lymphocytic lymphoma frequently does not accumulate Gallium Ga 67 sufficiently for unequivocal imaging; and the use of gallium with this histologic type of lymphoma is not recommended at this time.

Gallium Ga 67 localization cannot differentiate between tumor and acute inflammation; and other diagnostic studies must be added to define the underlying pathology.

Gallium Citrate Ga 67 Injection, as well as any other radioactive drugs, must be handled with care, and appropriate safety measures should be used to minimize external radiation exposure to clinical personnel. Care should also be taken to minimize radiation exposure to patients consistent with proper patient management.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential or whether Gallium Citrate Ga 67 Injection affects fertility in males or females.

Pregnancy Category C

Animal reproductive studies have not been conducted with Gallium Citrate Ga 67 Injection. It is also not known whether Gallium Citrate Ga 67 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Gallium Citrate Ga 67 Injection should be given to a pregnant woman only if clearly needed.

Ideally, examinations using radiopharmaceuticals, especially those elective in nature, in a woman of childbearing capability, should be performed during the first few (approximately 10) days following the onset of menses.

Nursing Mothers

Gallium Citrate Ga 67 Injection is excreted in human milk during lactation; therefore, formula feedings should be substituted for breast feedings.

Pediatric Use

Safety and effectiveness in the pediatric population has not been established.

Geriatric Use

Clinical studies of Gallium Citrate Ga 67 Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS: Severe itching, erythema, and rash were observed in one patient of 300 studied.

The rare occurrence of hypersensitivity reactions or allergic reactions, skin rash, and nausea have been reported in association with Gallium 67 use.

DOSAGE AND ADMINISTRATION: The recommended adult (70 kg) dose of Gallium Citrate Ga 67 Injection is 74-185 MBq (2-5 mCi). Gallium Citrate Ga 67 Injection is intended for intravenous administration only.

Approximately 10% of the administered dose is excreted in the feces during the first week after injection. Daily laxatives and/or enemas are recommended during the first week after injection until the final images are obtained in order to cleanse the bowel of radioactive material and minimize the possibility of false positive studies.

Studies indicate the optimal tumor to background concentration ratios are often obtained about 48 hours post-injection. However, considerable biological variability may occur in individuals, and acceptable images may be obtained as early as 6 hours and as late as 120 hours after injection.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Waterproof gloves should be worn during the handling procedures. With a shielded sterile syringe, aseptically withdraw the material for use. The expiration date of the drug is fourteen days after the date of manufacture.

RADIATION DOSIMETRY

The estimated absorbed radiation doses2 from an intravenous injection of 185 MBq (5 mCi) of Gallium Citrate Ga 67 are shown in Table 4.

TABLE 4. Dosimetry of Gallium Citrate Ga 67 Injection for Maximal Dose of 185 MBq (5 mCi)
mGy/
185 MBq
Rads/
5mCi
2MIRD Dose Estimate Report No.2, J. Nucl. Med. 14:755-6 (1973).
Whole Body 13.0 1.30
Skeleton 22.0 2.20
Liver 23.0 2.30
Bone Marrow 29.0 2.90
Spleen 26.5 2.65
Kidney 20.5 2.05
Ovaries 14.0 1.40
Testes 12.0 1.20
Gastrointestinal Tract
   Stomach 11.0 1.10
   Small Intestine 18.0 1.80
   Upper Large Intestine 28.0 2.80
   Lower Large Intestine 45.0 4.50

HOW SUPPLIED: Gallium Citrate Ga 67 Injection is supplied sterile and non-pyrogenic for intravenous use. Each mL contains 74 MBq (2 mCi) of Gallium Ga 67 on the calibration date, as a complex formed from 9 ng Gallium Chloride Ga 67, 2 mg of sodium citrate, 6.8 mg sodium chloride, and 9 mg benzyl alcohol/mL as preservative. The pH is adjusted to between 4.5-8 with hydrochloric acid and/or sodium hydroxide solution.

Vials are available in the following quantities of radioactivity: 244.2, 325.6, 488.4, and 732.6 MBq (6.6, 8.8, 13.2, and 19.8 mCi) of Gallium Citrate Ga 67.

NDC Number 11994-121

Store at controlled room temperature 20°-25°C (68°-77°F) [See USP].

The contents of the vial are radioactive and adequate shielding and handling precautions must be maintained.

This radiopharmaceutical is approved for distribution to persons licensed pursuant to the Code of Massachusetts Regulations 105 CMR 120.100 for the uses listed in 105 CMR 120.533 or under equivalent licenses of the U.S. Nuclear Regulatory Commission, an Agreement State, or a Licensing State.

Bristol-Myers Squibb
Medical Imaging

331 Treble Cove Road
N. Billerica, MA 01862 USA
For Ordering Tel. Toll Free: 800-225-1572
All Other Business: 800-362-2668
(For Massachusetts and International, call 978-667-9531)

Printed in U.S.A.

511945-0903
September 2003


Gallium Citrate Ga 67 (Gallium Citrate, Ga-67)
PRODUCT INFO
Product Code 11994-121 Dosage Form INJECTION, SOLUTION
Route Of Administration INTRAVENOUS DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Gallium Citrate, Ga-67 (Gallium Citrate, Ga-67) Active 2 MILLICURIE  In 1 MILLILITER
Sodium Citrate Inactive 2 MILLIGRAM  In 1 MILLILITER
Sodium Chloride Inactive 6.8 MILLIGRAM  In 1 MILLILITER
Benzyl Alcohol Inactive 9 MILLIGRAM  In 1 MILLILITER
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 11994-121-06 3.3 MILLILITER In 1 VIAL None
2 11994-121-08 4.4 MILLILITER In 1 VIAL None
3 11994-121-13 6.6 MILLILITER In 1 VIAL None
4 11994-121-19 9.9 MILLILITER In 1 VIAL None

Revised: 06/2006





1

fallium citrate ga 67, vallium citrate ga 67, ballium citrate ga 67, hallium citrate ga 67, yallium citrate ga 67, tallium citrate ga 67, gzllium citrate ga 67, gsllium citrate ga 67, gwllium citrate ga 67, gqllium citrate ga 67, gaklium citrate ga 67, gaplium citrate ga 67, gaolium citrate ga 67, galkium citrate ga 67, galpium citrate ga 67, galoium citrate ga 67, galluum citrate ga 67, galljum citrate ga 67, gallkum citrate ga 67, galloum citrate ga 67, gall9um citrate ga 67, gall8um citrate ga 67, galliym citrate ga 67, gallihm citrate ga 67, gallijm citrate ga 67, galliim citrate ga 67, galli8m citrate ga 67, galli7m citrate ga 67, galliun citrate ga 67, galliuk citrate ga 67, galliuj citrate ga 67, gallium xitrate ga 67, gallium vitrate ga 67, gallium fitrate ga 67, gallium ditrate ga 67, gallium cutrate ga 67, gallium cjtrate ga 67, gallium cktrate ga 67, gallium cotrate ga 67, gallium c9trate ga 67, gallium c8trate ga 67, gallium cirrate ga 67, gallium cifrate ga 67, gallium cigrate ga 67, gallium ciyrate ga 67, gallium ci6rate ga 67, gallium ci5rate ga 67, gallium citeate ga 67, gallium citdate ga 67, gallium citfate ga 67, gallium cittate ga 67, gallium cit5ate ga 67, gallium cit4ate ga 67, gallium citrzte ga 67, gallium citrste ga 67, gallium citrwte ga 67, gallium citrqte ga 67, gallium citrare ga 67, gallium citrafe ga 67, gallium citrage ga 67, gallium citraye ga 67, gallium citra6e ga 67, gallium citra5e ga 67, gallium citratw ga 67, gallium citrats ga 67, gallium citratd ga 67, gallium citratr ga 67, gallium citrat4 ga 67, gallium citrat3 ga 67, gallium citrate fa 67, gallium citrate va 67, gallium citrate ba 67, gallium citrate ha 67, gallium citrate ya 67, gallium citrate ta 67, gallium citrate gz 67, gallium citrate gs 67, gallium citrate gw 67, gallium citrate gq 67, gallium citrate ga 57, gallium citrate ga t7, gallium citrate ga y7, gallium citrate ga 77, gallium citrate ga 66, gallium citrate ga 6y, gallium citrate ga 6u, gallium citrate ga 68, allium citrate ga 67, gllium citrate ga 67, galium citrate ga 67, galium citrate ga 67, gallum citrate ga 67, gallim citrate ga 67, galliu citrate ga 67, galliumcitrate ga 67, gallium itrate ga 67, gallium ctrate ga 67, gallium cirate ga 67, gallium citate ga 67, gallium citrte ga 67, gallium citrae ga 67, gallium citrat ga 67, gallium citratega 67, gallium citrate a 67, gallium citrate g 67, gallium citrate ga67, gallium citrate ga 7, gallium citrate ga 6, agllium citrate ga 67, glalium citrate ga 67, galilum citrate ga 67, galluim citrate ga 67, gallimu citrate ga 67, galliu mcitrate ga 67, galliumc itrate ga 67, gallium ictrate ga 67, gallium ctirate ga 67, gallium cirtate ga 67, gallium citarte ga 67, gallium citrtae ga 67, gallium citraet ga 67, gallium citrat ega 67, gallium citrateg a 67, gallium citrate ag 67, gallium citrate g a67, gallium citrate ga6 7, gallium citrate ga 76, ggallium citrate ga 67, gaallium citrate ga 67, galllium citrate ga 67, galllium citrate ga 67, galliium citrate ga 67, galliuum citrate ga 67, galliumm citrate ga 67, gallium citrate ga 67, gallium ccitrate ga 67, gallium ciitrate ga 67, gallium cittrate ga 67, gallium citrrate ga 67, gallium citraate ga 67, gallium citratte ga 67, gallium citratee ga 67, gallium citrate ga 67, gallium citrate gga 67, gallium citrate gaa 67, gallium citrate ga 67, gallium citrate ga 667, gallium citrate ga 677, etc.

USA hospitals | Natural mosquito repellent | New 401k contribution limits | PMS | Blue waffles disease | Keratosis pilaris on face tretment


© Copyright by Drugspedia.net 2006-2007. All rights reserved